HEIP
CRL icon

Hudson Edge Investment Partners’s Charles River Laboratories CRL Stock Holding History

Hudson Edge Investment Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,084
Closed -$698K – 137
2020
Q3 		$698K Buy
+3,084
New +$640K 0.28% 67
2019
Q4 		– Sell
-3,794
Closed -$502K – 137
2019
Q3 		$502K Buy
+3,794
New +$509K 0.14% 98

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Hudson Edge Investment Partners's CRL Position: Q4 2020 in Review

Hudson Edge Investment Partners sold out of Charles River Laboratories (CRL) in Q4 2020, closing a stake of 3,084 shares — an estimated $698K sold.

Hudson Edge Investment Partners first reported a position in CRL in Q3 2019 and held it in 2 quarters. The position peaked at $698K in Q3 2020. 539 funds tracked by Wall St. Rank hold CRL as of Q4 2020.

  • Hudson Edge Investment Partners reported no remaining Charles River Laboratories position as of Q4 2020 after selling out during the quarter.
  • Hudson Edge Investment Partners sold 3,084 Charles River Laboratories shares in Q4 2020, an estimated $698K.
  • Hudson Edge Investment Partners first reported a position in Charles River Laboratories in Q3 2019 and held it in 2 quarters.
  • Hudson Edge Investment Partners's Charles River Laboratories position peaked at $698K in Q3 2020.
  • 539 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2020.

Based on Hudson Edge Investment Partners's 13F filing for Q4 2020, filed 8 Jan 2021.